melanogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-10 and is reviewed periodically as new material appears.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
A common substrate used in this type of system is glass. Depending if the system is open or closed, there would be either one or two layers of glass. The bottom layer of the device contains a patterned array of individually controllable electrodes. When looking at a closed system, there is usually a continuous ground electrode found through the top layer made usually of indium tin oxide (ITO). The dielectric layer is found around the electrodes in the bottom layer of the device and is important for building up charges and electrical field gradients on the device. A hydrophobic layer is applied to the top layer of the system to decrease the surface energy where the droplet will actually be in contact with. The applied voltage activates the electrodes and allows changes in the wettability of droplet on the device's surface. In order to move a droplet, a control voltage is applied to an electrode adjacent to the droplet, and at the same time, the electrode just under the droplet is deactivated. By varying the electric potential along a linear array of electrodes, electrowetting can be used to move droplets along this line of electrodes. Modifications to this foundation can also be fabricated into the basic design structure. One example of this is the addition of electrochemiluminescence detectors within the indium tin oxide layer (the ground electrode in a closed system) which aid in the detection of luminophores in droplets. In general, different materials may also be used to replace basic components of a DMF system such as the use of PDMS instead of glass for the substrate.
An ACS program chair, Gopal Coimbatore, said that without a proper forum the matter would never be discussed and, "with the world facing an energy crisis, it is worth exploring all possibilities." On 22–25 March 2009, the American Chemical Society meeting included a four-day symposium in conjunction with the 20th anniversary of the announcement of cold fusion. Researchers working at the U.S. Navy's Space and Naval Warfare Systems Center (SPAWAR) reported detection of energetic neutrons using a heavy water electrolysis setup and a CR-39 detector, a result previously published in Naturwissenschaften. The authors claim that these neutrons are indicative of nuclear reactions. Without quantitative analysis of the number, energy, and timing of the neutrons and exclusion of other potential sources, this interpretation is unlikely to find acceptance by the wider scientific community.
The requirement of arginine in the urea cycle is reduced, as dogs have a functional pyrroline-5-carboxylate synthase. Dogs have a functional delta 6 desaturase, hence no specific need for arachidonic acid. Dogs have a functional sulfinoalanine decarboxylase and can synthesise taurine from methionine and cysteine; however, some breeds have a genetic predisposition to taurine deficiency. Taurine supplementation is recommended for dogs at risk of taurine deficiency and dogs with dilated cardiomyopathy. Unlike cats, dogs and humans can use Vitamin D2 nearly as efficiently as they use Vitamin D3.
Rumbold had a meeting with the Polish Minister for Foreign Affairs, Stanisław Patek, who declared that he was disappointed with his people's behaviour and "spoke strongly about the tactlessness and rigidity of the Polish Military authorities". On 10 March, Beaumont wrote of numerous continuing difficulties being made by Polish officials and stressed the "ill-will between Polish and German nationalities and the irritation due to Polish intolerance towards the German inhabitants in the Corridor (now under their rule), far worse than any former German intolerance of the Poles, are growing to such an extent that it is impossible to believe the present settlement (borders) can have any chance of being permanent...". The Poles began to harden their position, and Rumbold reported to Curzon on 22 March 1920 that Count Stefan Przeździecki, an official of the Polish Foreign Office, had told Sir Percy Loraine, First Secretary at the legation at Warsaw, that the Poles questioned the impartiality of the Inter-Allied Commissions and indicated that the Polish government might refuse to recognise the results of the plebiscites. Infiltration attempts of Polish irregulars into the Marienwerder area were checked by Italian troops.
rescue The restoration of a defective cell or tissue to a healthy or normal condition, or the reversion or recovery of a mutant gene to its normal functionality, especially in the context of experimental genetics, where an experiment (e.g. a drug, cross, or gene transfer) resulting in such a restoration is said to rescue the normal phenotype.
Sources: en.wikipedia.org
In August 1914 Britain entered the First World War. Tolkien's relatives were shocked when he elected not to volunteer immediately for the British Army. In a 1941 letter to his son Michael, Tolkien recalled: "In those days chaps joined up, or were scorned publicly. It was a nasty cleft to be in for a young man with too much imagination and little physical courage." Instead, Tolkien, "endured the obloquy", and entered a programme by which he delayed enlistment until completing his degree. By the time he passed his finals in July 1915, Tolkien recalled that the hints were "becoming outspoken from relatives". He was commissioned as a temporary second lieutenant in the Lancashire Fusiliers on 15 July 1915. He trained with the 13th (Reserve) Battalion on Cannock Chase, Rugeley Camp near to Rugeley, Staffordshire, for eleven months. In a letter to Edith, Tolkien complained: "Gentlemen are rare among the superiors, and even human beings rare indeed." Following their wedding Lieutenant and Mrs. Tolkien took up lodgings near the training camp. On 2 June 1916, Tolkien received a telegram summoning him to Folkestone for posting to France. The Tolkiens spent the night before his departure in a room at the Plough & Harrow Hotel in Edgbaston, Birmingham. He later wrote: "Junior officers were being killed off, a dozen a minute. Parting from my wife then ... it was like a death."
Typically, people have fewer than 36 repeats in the polyQ region, which results in the normal production and cytoplasmic localization of the huntingtin. However, 36 or more repeats result in the production of a mutant huntingtin (mHTT), which causes degeneration of medium spiny neurons. Regions of the brain have differing amounts and reliance on these types of neurons and are affected accordingly. Generally, the number of CAG repeats is related to how much this process is affected, and accounts for about 60% of the variation of the age of the onset of symptoms. The remaining variation is attributed to the environment and other genes that modify the mechanism of HD. About 36 to 39 repeats result in a reduced-penetrance form of the disease, with a much later onset and slower progression of symptoms. In some cases, the onset may be so late that symptoms are never noticed. With very large repeat counts (more than 60), HD onset can occur below the age of 20, known as juvenile HD. Juvenile HD is typically of the Westphal variant that is characterized by slowness of movement, rigidity, and tremors. This accounts for about 7% of HD carriers.
== Diagnosis == Diagnosis of CSF leakage can be done by various imaging techniques, chemical tests of bodily fluid discharged from a head orifice, or clinical examination. The use of CT, MRI, and assays are the most common types of CSF leak instrumental tests. Many CSF leaks do not show up on imaging and chemical assays, thus such diagnostic tools are not definitive to rule out CSF leaks. A clinician may often depend upon patient history and exam to diagnose, for example: discharge of excessive amount of clear fluid from the nose upon bending over, the increase in headache following a Valsalva maneuver or the reduction of headache when the patient takes a prone position are positive indicators. A clinical exam is often used as a means to diagnose CSF leaks. Improved patient response to conservative treatment may further define a positive diagnosis. The lack of clinician awareness of the signs -symptoms and ailments- of a CSF leak is the greatest challenge to proper diagnosis and treatment, in particular: the loss of the orthostatic characteristic of headache and that every chronic CSF leaker will have a unique symptom set that as a whole contributes to the underlying condition, and diagnosis of, a CSF leak. The primary place of first complaint to a physician is a hospital emergency room. Up to 94% of those with sCSFLS are initially misdiagnosed. Incorrect diagnoses include migraines, meningitis, Chiari malformation, and psychiatric disorders. The average time from onset of symptoms until definitive diagnosis is 13 months.
== Chemistry == Tramadol is marketed as a racemic mixture of both R- and S-stereoisomers, because the two isomers complement each other's analgesic activities. The (+)-isomer is predominantly active as an opiate with a higher affinity for the μ-opiate receptor (20 times higher affinity than the (-)-isomer).
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.